Hideaki Sato

In March 2004, after leaving Kyoto University Graduate School of Agriculture, Department of Applied Life Sciences, he joined Gene Design Co., Ltd. as a researcher. After working as the general manager of Technical Service and Marketing Division and executive officer, I became the business director and acted as a counter to the acquisition by Ajinomoto . I was involved in the CpG-ODN clinical development as a malaria vaccine adjuvant. Luxna Biotech Co., Ltd., a start-up company from Osaka University (Co-founder Professor Satoshi Obika), and assumed the position of President in February 2018, and currently serves as President and CEO. I'm secretary of the Regulatory Science Subcommittee of the　Nucleic Acid Therapeutics Society of Japan.